NSCLC associated with both KRAS and TP53 mutations may present as a unique cancer subtype with distinct and aggressive biological behavior [45–49], resulting in many patients with metastatic KRAS+/TP53+ NSCLC not being selected for genomic profiling owing to poor functional status and organ dysfunction. This evidence concerns the gene KRAS and cancer.